Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1972 3
1973 3
1974 4
1975 3
1976 4
1977 4
1978 2
1979 14
1980 6
1981 8
1982 6
1983 10
1984 13
1985 4
1986 10
1987 8
1988 7
1989 6
1990 15
1991 6
1992 3
1993 15
1994 13
1995 18
1996 16
1997 23
1998 19
1999 14
2000 15
2001 12
2002 10
2003 12
2004 13
2005 10
2006 17
2007 12
2008 12
2009 4
2010 7
2011 1
2012 2
2013 6
2014 5
2015 2
2016 2
2017 1
2018 4
2019 2
2020 1
2021 1
2022 1
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

400 results
Results by year
Filters applied: . Clear all
Page 1
Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia.
Arenal Á, Ávila P, Jiménez-Candil J, Tercedor L, Calvo D, Arribas F, Fernández-Portales J, Merino JL, Hernández-Madrid A, Fernández-Avilés FJ, Berruezo A. Arenal Á, et al. J Am Coll Cardiol. 2022 Apr 19;79(15):1441-1453. doi: 10.1016/j.jacc.2022.01.050. J Am Coll Cardiol. 2022. PMID: 35422240 Clinical Trial.
Patients were 1:1 randomized to complete endocardial substrate-based catheter ablation or antiarrhythmic therapy (amiodarone + beta-blockers, amiodarone alone, or sotalol beta-blockers). The primary outcome was a composite of cardiovascular death, appropriate ICD shock, un …
Patients were 1:1 randomized to complete endocardial substrate-based catheter ablation or antiarrhythmic therapy (amiodarone + beta-blockers …
Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias: Multicenter Trial.
Miyoshi T, Maeno Y, Hamasaki T, Inamura N, Yasukochi S, Kawataki M, Horigome H, Yoda H, Taketazu M, Nii M, Hagiwara A, Kato H, Shimizu W, Shiraishi I, Sakaguchi H, Ueda K, Katsuragi S, Yamamoto H, Sago H, Ikeda T; Japan Fetal Arrhythmia Group. Miyoshi T, et al. J Am Coll Cardiol. 2019 Aug 20;74(7):874-885. doi: 10.1016/j.jacc.2019.06.024. J Am Coll Cardiol. 2019. PMID: 31416531 Free article. Clinical Trial.
METHODS: In this multicenter, single-arm trial, protocol-defined transplacental treatment using digoxin, sotalol, and flecainide was performed for singleton pregnancies from 22 to <37 weeks of gestation with sustained fetal SVT or AFL 180 beats/min. ...
METHODS: In this multicenter, single-arm trial, protocol-defined transplacental treatment using digoxin, sotalol, and flecainide was …
Antiarrhythmic drugs in patients with early persistent atrial fibrillation and heart failure: results of the RACE 3 study.
Al-Jazairi MIH, Nguyen BO, De With RR, Smit MD, Weijs B, Hobbelt AH, Alings M, Tijssen JGP, Geelhoed B, Hillege HL, Tieleman RG, Van Veldhuisen DJ, Crijns HJGM, Van Gelder IC, Blaauw Y, Rienstra M; RACE 3 Investigators. Al-Jazairi MIH, et al. Europace. 2021 Sep 8;23(9):1359-1368. doi: 10.1093/europace/euab062. Europace. 2021. PMID: 33899093 Free PMC article. Clinical Trial.
After baseline electrical cardioversion (ECV), 190 (77.6%) had AF recurrences; 108 (56.8%) received class I/III AADs; 19 (17.6%) flecainide, 36 (33.3%) sotalol, 3 (2.8%) dronedarone, 50 (46.3%) amiodarone. At 1-year 73 of 108 (68.0%) patients were in sinus rhythm, 44 (40.7 …
After baseline electrical cardioversion (ECV), 190 (77.6%) had AF recurrences; 108 (56.8%) received class I/III AADs; 19 (17.6%) flecainide, …
Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.
Singh BN, Deedwania P, Nademanee K, Ward A, Sorkin EM. Singh BN, et al. Drugs. 1987 Sep;34(3):311-49. doi: 10.2165/00003495-198734030-00002. Drugs. 1987. PMID: 3315621 Review.
Sotalol is a beta-adrenoceptor blocking agent devoid of intrinsic sympathomimetic activity, membrane stabilising actions and cardioselectivity. ...Sotalol also appears to be a promising agent in the control of ventricular arrhythmias. ...
Sotalol is a beta-adrenoceptor blocking agent devoid of intrinsic sympathomimetic activity, membrane stabilising actions and cardiose
QT prolongation and serum sotalol concentration are highly correlated following intravenous and oral sotalol.
Somberg JC, Preston RA, Ranade V, Molnar J. Somberg JC, et al. Cardiology. 2010;116(3):219-25. doi: 10.1159/000316050. Epub 2010 Aug 7. Cardiology. 2010. PMID: 20693799 Clinical Trial.
The equation QTc = 0.0342 (sotalol concentration) + 398 closely predicted actual QTc at any sotalol concentration. ...Low-dose sotalol caused significant QT prolongation. At similar concentrations, intravenous and oral sotalol caused similar QT and QTc …
The equation QTc = 0.0342 (sotalol concentration) + 398 closely predicted actual QTc at any sotalol concentration. ...Low-dose …
Rhythm versus rate control after ablation and pacing for paroxysmal atrial fibrillation: clinical implications of the PAF 2 trial.
Brignole M. Brignole M. Card Electrophysiol Rev. 2003 Jun;7(2):127-9. doi: 10.1023/a:1027403330926. Card Electrophysiol Rev. 2003. PMID: 14618035 Review.
In this multicenter randomized controlled trial, 68 patients with severely symptomatic paroxysmal atrial fibrillation were assigned, after successful atrioventricular junction ablation and pacing treatment, to antiarrhythmic drug therapy with amiodarone, propafenone, flecainide o …
In this multicenter randomized controlled trial, 68 patients with severely symptomatic paroxysmal atrial fibrillation were assigned, after s …
Pharmacokinetics and electrophysiological effects of sotalol hydrochloride in horses.
Broux B, De Clercq D, Decloedt A, Vera L, Devreese M, Gehring R, Croubels S, van Loon G. Broux B, et al. Equine Vet J. 2018 May;50(3):377-383. doi: 10.1111/evj.12765. Epub 2017 Nov 1. Equine Vet J. 2018. PMID: 29023952 Clinical Trial.
RESULTS: Calculated mean steady-state plasma concentrations determined by nonlinear mixed-effect modelling were 287 (range 234-339), 409 (359-458) and 543 (439-646) ng/mL for 2, 3 and 4 mg/kg bwt sotalol PO bid respectively. Sotalol significantly increased the QT in …
RESULTS: Calculated mean steady-state plasma concentrations determined by nonlinear mixed-effect modelling were 287 (range 234-339), 409 (35 …
Sotalol for paroxysmal supraventricular tachycardias.
Camm AJ, Paul V. Camm AJ, et al. Am J Cardiol. 1990 Jan 2;65(2):67A-73A; discussion 82A-83A. doi: 10.1016/0002-9149(90)90206-g. Am J Cardiol. 1990. PMID: 2403736 Review.
Used in adequate dosages, sotalol is efficacious in the conversion of acute supraventricular arrhythmias, an effect that is predictable on the basis of the drug's known electropharmacologic actions. Electrophysiologic studies have shown that both oral and intravenou …
Used in adequate dosages, sotalol is efficacious in the conversion of acute supraventricular arrhythmias, an effect that is predictab …
Effectiveness of sotalol for therapy of complex ventricular arrhythmias and comparisons with placebo and class I antiarrhythmic drugs.
Anderson JL. Anderson JL. Am J Cardiol. 1990 Jan 2;65(2):37A-42A; discussion 51A-52A. doi: 10.1016/0002-9149(90)90200-k. Am J Cardiol. 1990. PMID: 2403734 Review.
The frequency of ventricular premature complexes (VPCs) was reduced only 10% with placebo, 75% with low-dose sotalol (160 mg administered twice daily) and 88% with high-dose sotalol (320 mg administered twice daily) (both p less than 0.05 vs placebo). ...Thus, so
The frequency of ventricular premature complexes (VPCs) was reduced only 10% with placebo, 75% with low-dose sotalol (160 mg administ …
The Drug And Pace Health cliNical Evaluation (DAPHNE) study: a randomized trial comparing sotalol versus beta-blockers to treat symptomatic atrial fibrillation in patients with brady-tachycardia syndrome implanted with an antitachycardia pacemaker.
Capucci A, Botto G, Molon G, Spampinato A, Favale S, Proclemer A, Porfilio A, Marotta T, Vimercati M, Boriani G; DAPHNE Study Investigators. Capucci A, et al. Am Heart J. 2008 Aug;156(2):373.e1-8. doi: 10.1016/j.ahj.2008.01.032. Epub 2008 Jun 9. Am Heart J. 2008. PMID: 18657671 Clinical Trial.
BACKGROUND: Atrial tachyarrhythmias (ATAs) are mainly treated by pharmacologic therapy for rate control or rhythm control. The aim of our study was to compare sotalol (S) versus beta-blocking agents (BB) in terms of prevention of ATA, cardioversions (CVs), and cardi …
BACKGROUND: Atrial tachyarrhythmias (ATAs) are mainly treated by pharmacologic therapy for rate control or rhythm control. The aim of our st …
400 results